Kestra Medical Technologies Ltd. (KMTS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Travis Steed from Bank of America Securities maintained a Buy rating on the stock and has a $30.00 price target.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Travis Steed has given his Buy rating due to a combination of factors including Kestra Medical Technologies Ltd.’s strategic salesforce expansion and market growth potential. The company has increased its sales territories significantly, with plans to continue this growth responsibly, ensuring high-quality service and coverage in key markets. This expansion is expected to enhance productivity and capture a larger market share.
Additionally, Kestra is witnessing positive signs of market growth and share capture, particularly with its ASSURE product. The company is effectively converting physicians from competitors, leading to a notable increase in prescription rates. Furthermore, Kestra’s financial outlook is promising, with expectations of achieving a 70% gross margin and a 25% EBITDA margin as revenue grows. These factors contribute to the optimistic view of Kestra’s future performance, justifying the Buy rating.